Preparation of ccMOs
General Synthetic Procedures. All reactions were carried out using glassware except for morpholino couplings, which were performed in microcentrifuge tubes. All other reagents and solvents were purchased from commercial sources and used without further purification unless specifically noted. 1 H and 13 C NMR were recorded on a Bruker Avance III HD 500 MHz or 600 MHz spectrometer. UV spectra for MO quantification were recorded on a Nanodrop 2000c. HPLC (analytical and preparative) was performed on an Agilent Infinity series system with an autosampler and diode array detector using Zorbax eclipse C-18 reverse phase columns. HRMS/LC-MS was performed on an Agilent 6540 HD Accurate Mass QTOF/LC/MS with electrospray ionization (ESI). -5,11-dimethyl-6,12-dioxo-7-oxa-2,5,11-triazaheptadecan-17 -oic acid (6) . Alcohol 5 (92 mg, 0.155 mmol), prepared using literature protocol, 1 was added to a solution of carbonyldiimidazole (628 mg, 3.87 mmol) in CH 2 Cl 2 (25 mL). The reaction was monitored by TLC using a 1:1 acetone/chloroform solution. When TLC indicated the disappearance of starting material (~15 min), water (5 mL) was added and the organic layer separated, dried over anhydrous Na 2 SO 3 , filtered, and evaporated in vacuo. The remaining residue was dissolved in CH 2 Cl 2 and the resulting solution cooled in ice bath. N,N′-Dimethylethylenediamine (2 mL) was added rapidly and the reaction was monitored by TLC until completion (~15 min). Water (5 mL) was added and the organic layer separated and evaporated in vacuo. The resulting residue was dissolved in a solution of 1:1 acetonitrile/0.4 N NaOH (30 mL). The resulting solution was stirred in the dark until LC-MS indicated that the benzenesulfonyl group was removed and the ester was hydrolyzed (3-12 h). The reaction was neutralized to pH 8 followed by evaporation of the solvent in vacuo. The remaining residue was purified by HPLC (acetonitrile/water) to afford 6 as a yellow gum (30.3 3,6,12-trimethyl-2,7,13-trioxo-8-oxa-3,6,12-triazaoctadecan-18 -oic acid (7) . Amine 6 (30.3 mg, 0.055 mmol) was stirred in dry acetonitrile (25 mL). DIEA (58 µL, 0.33 mmol) was added followed by chloroacetyl chloride (21.5 µL, 0.27 mmol). The resulting solution was stirred until LC-MS indicated the presence of the amide and phenolic ester (~15 min). The solvent was removed in vacuo and the resulting residue was dissolved in water (4 mL) and TFA (200 µL) and stirred until LC-MS indicated that the phenolic ester was hydrolyzed. The solvent was evaporated in vacuo and the resulting residue was purified by HPLC (acetonitrile/water) to provide 7 as a sticky gum (11.3 
8-(8-Bromo-7-hydroxyquinolin-2-yl)

9-(8-Bromo-7-hydroxyquinolin-2-yl)-1-chloro-
7-((2-Methoxyethoxy)methoxy)-2-methylquinoline-8-carbonitrile (8).
A mixture of 7-hydroxy-2-methylquinoline-8-carbonitrile (1.4 g, 7.4 mmol) prepared as previously described, 2 and diisopropylethylamine (1.09 mL, 9.7 mmol) were dissolved in anhydrous CH 2 Cl 2 (35 mL). A solution of methoxyethoxymethyl chloride (1.1 mL 9.7 mmol) in CH 2 Cl 2 (4 mL) was then added to the solution via addition funnel dropwise over 30 minutes. The reaction mixture was stirred for three hours at room temperature under nitrogen and monitored by TLC (hexanes/EtOAc 1:3). The solvent was removed in vacuo, and the residue was dissolved in EtOAc (150 mL) and washed twice with water (50 mL) and then dried over anhydrous Na 2 SO 4 . Solvent was removed in vacuo, and the residue was purified by silica gel column chromatography (hexanes/EtOAc 1:1) to yield the product as a yellow oil (1. (12) . To a solution of 11 (1.2 g, 3.5 mmol) in THF (100 mL) was added 2.0 M methylamine solution in MeOH (2.6 mL, 5. mmol) and two drops of acetic acid. After 30 min, sodium acetoxy borohydride (970 mg, 4.6 mmol) was added and stirred at rt until LC-MS indicated that it was complete (3-12 h). The reaction was quenched with 0.4 N NaOH, extracted in CH 2 Cl 2 , and evaporated to a crude mixture containing 12 (1.3 g) that was immediately taken on to the next step: HRMS-ESI-LC-MS-Q-TOF (m/z) [ (14) . A solution of 13 (250 mg, 0.553 mmol) in CH 2 Cl 2 (4 mL) was added to a solution of carbonyl diimidazole (2.0 g, 12.3 mmol) in CH 2 Cl 2 and the resulting solution was stirred until LC-MS indicated that the reaction was complete (~10 min). Water was added and the mixture was partitioned and the aqueous phase removed. Additional CH 2 Cl 2 (20 mL) was added and the resulting solution was cooled to 0 °C. N,NDimethylethylene diamine (2.5 mL) was added and the resulting solution was stirred until LC-MS indicated that the reaction was complete (~10 min). The solvent was removed in vacuo and the resulting residue was dissolved in CH 2 Cl 2 . The organic layer was washed with H 2 O (5 mL) and dried with sodium sulfate, and the solvent removed in vacuo (it is critical at this stage to avoid exposing the free amine to acidic workups to prevent reversion of the carbamate to starting material). The resulting residue was dissolved in a solution of diispropylethylamine (251 µL, 1.02 mmol) in CH 2 Cl 2 (5 mL) and the resulting solution cooled to 0 °C. Chloroacetyl chloride (81 µL, 1.02 mmol) was added and the reaction was stirred for 4 h. Water was added, and the resulting mixture was extracted into CH 2 Cl 2 . The solvent was removed in vacuo and the resulting material was purified using column chromatography starting with a gradient of chloroform and THF (0 -100% THF over 20 minutes). Re-dissolving the material in CH 2 Cl 2 and washing with water (3 times) removed the remaining impurities. The CH 2 Cl 2 was removed in vacuo to provide carbamate 14 as a yellow oil (93 mg, 0.14 mmol, 25%). 
Methyl 1-chloro-9-(8-cyano-7-((2-methoxyethoxy)methoxy)quinolin-2-yl)-3,6,12-trimethyl-2,7,13-trioxo-8-oxa-3,6,12-triazaoctadecan-18-oate
2,5-Dioxopyrrolidin-1-yl 1-chloro-9-(8-cyano-7-hydroxyquinolin-2-yl)-3,6,12-trimethyl-2,7,13-trioxo-8-oxa-3,6,12-triazaoctadecan-18-oate (1b)
. A solution of 14 (36 mg, 0.074 mmol) was prepared by dissolving 14 into 1:1 acetonitrile/water (20 mL) with 5% TFA. The mixture was stirred at 40 °C in the dark for 12 hours. The reaction was monitored by HPLC or LC-MS for the hydrolysis of both protecting group and methyl ester. The solvent was removed in vacuo to dryness forming an orange gum. The material was then dissolved in dry acetonitrile and then added pyridine (12 µL, 0.148 mmol) and dissuccinimidyl carbonate (38 mg, 0.148 mmol). The reaction was monitored by HPLC or LC-MS (2 h-overnight). Upon completion, the solvent was removed in vacuo and the residue was purified by silica gel column chromatography (methanol/CH 2 Cl 2 1:9) to yield 1b (29 mg, 0.043 mmol, 58%) as a sticky solid. (16) . To a cold solution (0 °C) of tetraethylene glycol 15 (10.18 g, 52.4 mmol) in THF (3 mL), NaOH (356 mg, 8.9 mmol) was added. A solution of para-toluenesulfonyl chloride (1.0 g, 5.2 mmol) in THF (10 mL) was added dropwise with a dropping funnel and the resulting mixture was stirred at 0 °C for 3 h. The reaction mixture was quenched with water (50 mL), extracted with CH 2 Cl 2 (3 x 50 mL) and the organic phase washed with water (2 x 50 mL). After drying over MgSO 4 (17) . Sodium azide (1.6 g , 24.7 mmol) was added to a solution of 16 (1.7 g, 4.9 mmol) in EtOH (25 mL). The mixture was heated to 70 °C and stirred for 12h. After cooling water (25 mL) was added and the mixture concentrated to a third of his volume. The mixture was extracted with EtOAc (3 x 50 mL) and washed with with water (2 x 50 mL). After drying over MgSO 4 (18) . A solution of 17 (0.2 g, 0.9 mmol) in MeOH (8 mL) was charged in a pressure vessel and stirred under hydrogen atmosphere (4 bars) for 3 h. The mixture was then diluted with MeOH (20 mL) and filtered over a celite pad. Solvent was evaporated furnishing primary amine 18 as an oil (170 mg, 0.9 mmol, 97%):
2-(2-(2-(2-Hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethan-1-ol
2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethan-1-ol
1 H NMR (500 MHz, CDCl 3 ) (21) . To a cold solution of 20 (22 mg, 0.03 mmol) in DMF (1 mL), a solution of 18 (10 mg, 0.05 mmol) was added dropwise, followed by EDC (7 mg, 0.03 mmol), TBTU (11 mg, 0.03 mmol) and DIEA (6 µL, 0.03 mmol). Temperature was raised to rt and the mixture was stirred in the dark for 12 h. MeOH (10 mL) was added and the mixture was evaporated. The residue was purified by silica gel chromatography (10% MeOH in CH 2 Cl 2 ) followed by a second purification by prepHPLC (water/CH 3 CN) affording pure compound 21 ( -10  0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180  190  200  210 f1 ( 
22-(8-Cyano-7-hydroxyquinolin-2-yl)-1-hydroxy-19-methyl-13,18-dioxo-3,6,9-trioxa-12,19-diazadocosan-22-yl (2-(2-(ethylthio)-N-methylacetamido)ethyl)(methyl)carbamate
UV-vis Spectra
UV-vis spectra were recorded on a Thermo Scientific NanoDrop 2000c spectrophotometer with a spectral window measuring from 200 to 800 nm. Single drops of aqueous solution of substrates were analyzed versus drops of blank solution obtaining the final absorbance spectrum. The measurement was repeated in triplicate and the absorbencies averaged. Final e values at l max and l = 405 nm were obtained from the Beer-Lambert law: e = A(cl) -1 . Figure S1 . UV-vis spectrum of CyHQ-gad1b-cMO (4b-1) in water. Protein extracts were prepared from pools of 30-100 zebrafish larvae at 3, 4, 5, 6, and 7 dpf. Protein extracts prepared from adult zebrafish brain (AB) and adult mouse brain (MB) served as positive controls. The same blot was probed for Gad1, Gad2, and GAPDH. Gad1 was detected using a mouse monoclonal to GAD 67 (K-87, cat # sc-58531, Santa Cruz Biotechnology Inc), which was raised against amino acids 87-106 (RFRRTETDFSNLFARDLLPA) of human GAD 67 . This antibody reacts with the Gad1b protein in zebrafish; however, it is not yet known if the antibody detects Gad1a (VanLeuven, A. J.; Ball, R. E.; Gunderson, C. E.; Lauderdale, J. D., submitted). The presumptive epitope in Gad1b is RFTRDETDFSNLFARDLLPA and the presumptive epitope in Gad1a is RFRRTETDFSNLYARDLLPA; changes from the human sequence are denoted in bold underline. This antibody does not react with Gad2 protein from zebrafish. Gad2 was detected using a rabbit polyclonal to zebrafish Gad2 (cat #55772, AnaSpec, Inc., Freemont, CA); this antibody does not detect Gad1b (or Gad1a, presumably) in zebrafish. GAPDH served as a loading control. (A) Gad1: Three isoforms of Gad1 were detected in zebrafish: an ~67-kDa isoform predominant in extracts prepared from adult zebrafish brain and larvae at 3 and 4 dpf; a ~62 kDa weight isoform predominant in extracts prepared from larvae at 5, 6, and 7 dpf; and a ~44 kDa isoform present in extracts prepared from larvae at 6 and 7 dpf. The 67 kDa isoform was comparable in size to that detected in adult mouse brain. The smaller isoforms are likely due to translation initiating from an internal ATG and/or alternative splicing. (B) Gad2: Two isoforms were detected in zebrafish: a ~65 kDa isoform was present in larvae and adult protein extracts; a higher molecular weight isoform was present in larvae at 3 and 4 dpf as well as in mouse brain. Figure S14. Sequence of gad1b exons 2 through 4.
To provide standardized coordinates, 3 the first base of the ATG initiation codon in the gad1b cDNA reference sequence is denoted as nucleotide 1, and the first methionine is denoted as M 1 . ATG codons located upstream of the anti-GAD 67 epitope (denoted in bold) are highlighted in yellow; the location of each is given relative to M 1 in the full-length protein. The predicted molecular weights of hypothetical Gad1b proteins associated with translation initiation from each ATG in exons 2 through 4 are shown in the associated table. (A) Red bars represent percent of injected animals that exhibited normal morphology at 1 dpf as determined by visual inspection under a microscope, and blue bars represent the percent of injected animals alive at 1 dpf. The total number of injected embryos obtained from 5-7 independent experiments is given for controls and gad1b MO amounts equal to or less than 0.5 ng. A single injection set was performed for gad1b MO amounts of 1 ng and 3 ng. Error bars represent SEM. Embryos in the control injection set received injection buffer only. (B) Western blot analysis of Gad1 protein in pools of embryos injected with different amounts of gad1b MO. Protein extracts were prepared from 30-100 embryos at 3 dpf per given MO dose. Blots were probed using a mouse monoclonal to GAD 67 (K-87, cat # sc-58531, Santa Cruz Biotechnology Inc.). Protein extracts prepared from WT embryos, adult zebrafish brain (AB) and adult mouse brain (MB) served as positive controls. GAPDH served as a loading control. The optimal dose of gad1b MO was determined to be 0.3 ng per embryo (1-nL injection volume ´ 0.3 ng gad1b MO/nL). Western blot analysis of Gad1 protein in pools of zebrafish embryos injected with 0.3 ng gad1b translation blocking MO at the 1-4 cell stage. Protein extracts were prepared from 30-100 embryos at 3, 5, and 7 dpf. Blots were probed using a mouse monoclonal to GAD 67 (K-87, cat # sc-58531, Santa Cruz Biotechnology Inc.). Protein extracts prepared from WT embryos, adult zebrafish brain (AB) and adult mouse brain (MB) served as positive controls. GAPDH served as a loading control. (A) Red bars represent percent of injected animals that exhibited normal morphology at 1 dpf as determined by visual inspection under a microscope, and blue bars represent the percent of injected animals alive at 1 dpf. The total number of injected embryos obtained from 5-7 independent experiments is given for controls and gad2 MO amounts equal to or less than 1.5 ng. A single injection set was performed for gad2 MO amounts of 3 ng. Error bars represent SEM. Embryos in the control injection set received injection buffer only. (B) Western blot analysis of Gad2 protein in pools of embryos injected with different amounts of gad2 MO. Protein extracts were prepared from 30-100 embryos at 3 dpf per given MO dose. Blots were probed using a rabbit polyclonal to zebrafish Gad2 (cat #55772, AnaSpec, Inc., Freemont, CA). Protein extracts prepared from adult zebrafish brain (AB) and WT embryos served as positive controls; protein extract prepared from adult mouse brain (MB) was included to test species specificity. GAPDH served as a loading control. The optimal dose of gad2 MO was determined to be 1 ng per embryo (1-nL injection volume x 1.0 ng gad2 MO/nL). Western blot analysis of Gad2 protein in pools of zebrafish embryos injected with 1 ng gad2 translation blocking MO at the 1-4 cell stage. Protein extracts were prepared from 30-100 embryos at 3, 5, and 7 dpf. Blots were probed using a rabbit polyclonal to zebrafish Gad2 (cat #55772, AnaSpec, Inc., Freemont, CA). Protein extracts prepared from WT embryos and adult zebrafish brain (AB) served as positive controls; protein extract prepared from adult mouse brain (MB) was included to test species specificity. GAPDH served as a loading control. Under these conditions, the gad2 MO was effective at blocking translation of the Gad2 protein through 5 dpf. Western blot analysis of Gad1 protein in pools of zebrafish embryos injected at the 1-4 cell stage with 0.5 ng BHQ-gad1b-ccMO or CyHQ-gad1b-ccMO under red-light conditions. One half of each pool was then exposed to light to uncage the ccMOs. All fish were then raised to 3 dpf under the same conditions. Protein extracts were prepared from 15-30 embryos per injection set at 3 dpf and quantitated using the bicinchoninic acid (BCA) assay (Pierce). Equal amounts of extract were loaded in each lane. Blots were probed using a mouse monoclonal to GAD 67 (K-87, cat # sc-58531, Santa Cruz Biotechnology Inc.). The blot was stripped and reprobed for GAPDH. Protein extracts prepared from uninjected embryos served as controls. (A) Titration of gad1b splice blocking MOs assessed at 3 dpf. (B) The gad1b splice blocking MO at 1.25 ng is effective through 3 dpf. Western blot analysis of Gad1 protein in pools of zebrafish embryos injected at the 1-4 cell stage with gad1b splice blocking MO. Protein extracts were prepared from 15-30 embryos per injection set and quantitated using the bicinchoninic acid (BCA) assay (Pierce). Equal amounts of extract were loaded in each lane. Blots were probed using a mouse monoclonal to GAD 67 (K-87, cat # sc-58531, Santa Cruz Biotechnology Inc.) and a rabbit polyclonal to GAPDH (ab9484, Abcam, Cambridge, MA. Protein extracts prepared from uninjected embryos served as controls.
Design of Splice Blocking Morpholinos. Splice blocking Morpholinos (MO) were designed to bind to the exon 2-intron 2 junction of gad1b and the exon 3-intron 3 junction of gad2. The first translation initiation codon for gad1b is in exon 2, and the translation initiation codon for gad2 is located in exon 1. Five base mismatch controls were used. The sequences of the MOs are: gad1b Splice Blocker: 5'-TGTGATTTGTGGTGATTTACCTGTT-3' gad1b Splice Control: 5' TGTcATTTcTGGTcATTTACgTcTT-3' gad2 Splice Blocker: 5'-GCGTTATCCAGAGAGACCTACTTGT-3' gad2 Splice Control: 5' GCcTTATgCAcAGAcACCTACTTcT-3' Figure S21 . Knockdown of gad1b using a splice blocking MO causes morphological defects in the zebrafish head skeleton.
Ventral view of alcian stained larvae at 7 dpf. Embryos injected with gad1b splice blocking mismatch control MOs exhibit normal skeletal development (n=14/14). Embryos injected with 1.25 ng of gad1b splice blocking MOs exhibit altered cartilage development (n=10/10) comparable or more severe than embryos injected with 0.3 ng gad1b translation blocking MO; this fish is comparable to those used to prepare the flat mounts show in Supplemental Figure  S10 . , and snail1b (M-P). Gene expression was assessed by whole-mount mRNA in situ hybridization. The head skeleton in zebrafish, as in mammals, develops from cranial neural crest (CNC) cells. In zebrafish, the premigratory neural crest in the head is located lateral to the developing neural keel during the 1-to 10-somite stages (9 through 14 hpf) 4, 5 and express genes associated with neural crest (e.g., prdm1a, tfap2a, foxd3, snail1b). [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] (A-D) The expression of prdm1a is comparable to wild-type animals in both trunk and cranial neural crest populations (D); (E-H) the pattern of foxd3 expression appeared expanded in gad1b morphants (compare regions denoted with arrows and bracket between wild-type and morphant embryos); foxd3 expression is normally downregulated in wild-type embryos upon CNC migration; 14 (I-L) expression of tfap2a appears expanded in gad1b morphants (arrows); (M-P) snail1b expression is diminished in the anterior brain in gad1b morphants (circles denote position of eyes). 18, 19 (C,D) and acridine orange (E,F). Beginning ~15 hpf, CNC cells delaminate from the ectoderm overlying the dorsal neural tube in a wave originating at the midbrain and progressing along in caudal direction and migrate as separate streams into the pharyngeal arches. 4, 5 The bulk of this migration occurs between 18 and 24 hpf. During migration, these cells continue to proliferate and begin to express genes associated with formation and differentiation of mesenchymal condensations. [20] [21] [22] Neurocranial precursors originate in the midbrain region and migrate between the eyes to form the palatal shelves, and the pharyngeal arches are populated by CNCs that emigrate from the hindbrain. UPPER Panels: (A-F) Lateral view of ISH for dlx2a in wild-type, gad1b morphant (translation blocking), pentylenetetrazol (PTZ) treated, picrotoxin (PTX) treated, sacolfen treated and muscimol treated embryos at the 10-12 somite stage. (A-D) dlx2a expression is reduced in embryos treated with 15 mM PTZ or 1 mM PTX. PTZ and PTX are both GABA A receptor antagonists. The reduction in expression is similar to that observed in gad1b morphant animals (arrow and bracket). Expression in the pharyngeal arches is almost absent, when compared to wildtype animals; (E) Animals treated with 100 μM saclofen, a GABA B antagonsist, exhibited dlx2a expression comparable to that of wild type animals (arrow and arrowheads); (F) Animals treated with 50 μM muscimol (a GABA A agonist) exhibited a modest increase of dl2a expression throughout the embryos, when compared to wild type animals. LOWER Panels: Lateral (A,C,E,G,I,K) and dorsal (B,D,F,H,J,L) views of ISH for foxd3 in wildtype, gad1b morphant (translation blocking), pentylenetetrazol (PTZ) treated, picrotoxin (PTX) treated, sacolfen treated and muscimol treated embryos at the 10-12 somite stage. The pattern of foxd3 expression appeared expanded in embryos treated with 15 mM PTZ or 1 mM PTX comparable to gad1b morphants. The pattern of foxd3 expression in embryos treated with 100 μM saclofen or 50 μM muscimol was similar to that observed in wild-type embryos.
These findings support the idea that GABA signaling through the ionotropic GABA A receptor plays a role in cranial neural crest cells. Figure S26 . Knockdown of gad1b and gad2 causes an increase in native neurological activity in 3 dpf zebrafish larvae.
(A) Native neurological activity within the optic tectum of 3 dpf wild-type animals. (B) Knockdown of gad1b causes an increase in the electrical activity observed in the optic tectum; note presence of events with amplitudes >0.3 mV. (C) Knockdown of gad2 causes an increase in the electrical activity observed in the optic tectum; note increase in numbers of high frequency, lowamplitude events compared to WT. (D) gad1b/gad2 double morphants exhibit a significant increase in neurological activity, when compared with either wild-type or single morphant animals. Large amplitude (> 0.6 mV) events develop and occur in small clusters, separated by smaller (0.15 mV) events. (E) WT 3 dpf larva exposed to 15 mM PTZ for comparison. Figure S27 . The gad1b synthetic mRNA is translated into Gad1b protein and can rescue morphant phenotype.
(A) Western blot analysis of Gad1 protein in pools of zebrafish embryos injected at the 1-4 cell stage with 0.1 ng capped gad1b mRNA, 0.3 ng gad1b translation blocking MO, or co-injected with 0.1 ng capped gad1b mRNA and 0.3 ng gad1b translation blocking MO. Protein extracts were prepared from 15 embryos at 1 dpf and quantitated using the bicinchoninic acid (BCA) assay (Pierce). Equal amounts of extract were loaded in each lane. Blots were probed using a mouse monoclonal to GAD 67 (K-87, cat # sc-58531, Santa Cruz Biotechnology Inc.). Protein extracts prepared from WT embryos and adult zebrafish brain (AB) served as positive controls. Injection of exogenous gad1b mRNA correlated with the detection of two Gad1 isoforms: one of the expected size of ~67 kDa and a second, smaller protein of ~61 kDa weight. The second isoform likely arose as a result of translation initiating from an internal in-frame ATG, most likely the ATG located in the region of the transcript corresponding with gad1b exon 3. See Figure  S14. (B) Titration of gad1b synthetic mRNA for rescue experiments. Red bars represent the percent of injected animals (out of 100) that showed normal morphology; Blue bars represent the percent of injected animals alive at 24hpf. Error bars represent SEM. 0.05 ng of synthetic gad1b mRNA was sufficient to rescue early development of embryos injected with 0.3 ng gad1b translation blocking MO. (C-J). Representative images of embryos from rescue experiments. (C) Wild-type embryo for comparison. (E, G, I, J) Wild-type embryos injected with 0.05 ng synthetic gad1b mRNA (E), 0.05 ng synthetic beta-galactosidase mRNA (G), 1.6 ng synthetic gad1b mRNA (I), or 1.6 ng synthetic beta-galactosidase mRNA (J). (D, F, H) Embryos injected with 0.3 ng gad1b translation blocking MO and (F) 0.05 ng synthetic gad1b mRNA or (H) 0.05 ng synthetic beta-galactosidase mRNA. Embryos co-injected with 0.05 ng synthetic gad1b mRNA and 0.3 ng gad1b translation blocking MO (F) exhibited more normal development than embryos injected with MO alone (D) or co-injected with synthetic beta-galactosidase mRNA (H), which exhibited smaller eyes and an altered distribution of the presumptive head mesenchyme (asterisks). Embryos injected with 0.05 ng synthetic gad1b mRNA (E), 0.05 ng synthetic betagalactosidase mRNA (G), or 1.6 ng synthetic beta-galactosidase mRNA (J) exhibited normal morphological development. (I) Embryos injected with 1.6 ng synthetic gad1b mRNA exhibited altered head morphology similar to that observed in gad1b morphants. Scale bar A = 0.5 mm, applies to all panels.
Preparation of Synthetic gad1b mRNA
Construction of the gad1b clone for preparing synthetic gab1b mRNA. The gad1b sequence was PCR-amplified using DreamTaq DNA Polymerase (Thermo Scientific) following manufacture's recommendations from cDNA prepared from adult brain using a forward primer, zf gad1b RNA rescue-F1-EcoRI: 5¢-attaGAATTCACCATGGCAAGCAGCGCTCCATCTTCCTCGGCTGGTGATATG-3¢ (52 nucleotides, 69.6 Tm) and reverse primer, zf gad1n RNA rescue-R1-XhoI: 5¢-attaCTCGAGTTACAGATCCTGACCGAGCC-3¢ (30 nucleotides, 62.1 Tm).
The primers were designed to amplify the native gad1b open reading frame while destroying the gad1b translation MO target site without codon alteration. Changes to the endogenous gad1b sequence around the translation initiation ATG (underlined) are denoted in bold in the forward primer. The sequence around the ATG meets the rules established for a Kozak sequence. 24, 25 The primers included the following design features: 1) 4 nucleotides (ATTA), denoted in lowercase in the primer sequence, were added to the 5¢ end of each primer to ensure efficient cutting by restriction enzymes; and 2) EcoRI and XhoI sites were incorporated into the forward and reverse primers, respectively. The PCR amplicon was cloned into the EcoRI/XhoI sites of a modified pCS2+ vector 26, 27 in which CMV promoter activity was destroyed by digestion with SalI and HindIII, subjected to end-repair using DNA Polymerase I large (Klenow) fragment (New England BioLabs), and self-ligated. The destruction of the CMV promoter permitted recovery of intact gad1b clones. Candidate clones were validated by sequencing.
In vitro transcription.
Capped gad1b mRNA lacking the gad1b translation blocking MO target sequence and betagalactosidase mRNA (control, pCS2+nuclear localized lac Z) were synthesized in vitro using the mMessage mMachineTranscription Kit (Life Technologies, Grand Island, NY) following manufacturer's recommendations. Template plasmids were linearized by NotI digestion. RNA was synthesized using the using SP6 RNA polymerase. Reaction products were quantitated spectrophotometrically and assessed for size by denaturing gel electrophoresis.
Microinjection.
Capped mRNA was injected using pressure into one to four-cell stage embryos following standard protocols. [28] [29] [30] [31] For rescue experiments, capped mRNA was co-injected with MOs. The same concentrations of beta-galactosidase mRNA were used in control experiments.
